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Abstract
Background: Relapsed acute lymphoblastic leukemia (ALL) is one of the main causes of mortality in childhood
malignancies. Previous genetic studies demonstrated that chemoresistant ALL is driven by activating mutations in
NT5C2, the gene encoding cytosolic 5´-nucleotidase (cN-II). However, molecular mechanisms underlying this
hyperactivation are still unknown. Here, we present kinetic and structural properties of cN-II variants that represent
75 % of mutated alleles in patients who experience relapsed ALL (R367Q, R238W and L375F).
Results: Enzyme kinetics measurements revealed that the mutants are consitutively active without need for
allosteric activators. This shows that hyperactivity is not caused by a direct catalytic effect but rather by
misregulation of cN-II. X-ray crystallography combined with mass spectrometry-based techniques demonstrated
that this misregulation is driven by structural modulation of the oligomeric interface within the cN-II
homotetrameric assembly. These specific conformational changes are shared between the studied variants, despite
the relatively random spatial distribution of the mutations.
Conclusions: These findings define a common molecular mechanism for cN-II hyperactivity, which provides a solid
basis for targeted therapy of leukemia. Our study highlights the cN-II oligomerization interface as an attractive
pharmacological target.
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Background
Cytosolic purine 5´-nucleotidase (cN-II; EC 3.1.3.5) de-
phosphorylates purine nucleotide monophosphates with
canonical activity towards inosine monophosphate
(IMP) [1]. IMP represents a branch point intermediate
linking major routes of purine metabolism, including de
novo synthesis, the salvage pathway and oxidative deg-
radation [2]. Therefore, cN-II serves as an essential regu-
latory element to maintain the balance of the nucleotide
pool [3]. Unlike other nucleotidases, it is subject to com-
plex allosteric regulation.
The activity of cN-II is regulated according to the ad-
enylate energy charge of cells [4]. In a low energy state
or anoxia, adenosine triphosphate (ATP) is depleted and
free phosphate accumulates, leading to inhibition of
cN-II. This hinders degradation of IMP and contributes
to consequent losses of purine nucleotides via diffusion
of dephosphorylated nucleosides.
The cN-II protein assembles into functional homote-
tramers [5], with each subunit comprising 561 amino
acid residues [6]. The tetrameric assembly is formed by
two identical dimers in which a dimerization site (inter-
face A) comprises 53 intersubunit contacts. These two
dimers are held together by interface B, which contains
28 interacting residues from each subunit [7].
The cN-II structure possesses the overall fold characteris-
tic of the haloacid dehalogenase superfamily: an α/β
Rossmann-like “core domain” and a smaller “cap domain.”
The active site of cN-II is formed by three highly conserved
regions: motif I (D52, D54, T56, and L57), motif II (T249),
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and motif III (K292, D351, and D359) [8]. To achieve a full
catalytic activity, cN-II requires the presence of adenylate
compounds, such as ATP, adenosine diphosphate or diade-
nosine tetraphosphate [1]. Binding of these allosteric activa-
tors induces a disorder-order transition of helix A, which
spans residues 355–365. This transition places residues in
the catalytic pocket into an appropriate orientation to co-
ordinate the catalytically essential magnesium ion [9]. In
addition, the cN-II sequence contains an acidic region con-
sisting of 15 glutamates at the C terminus, which has been
suggested to be involved in the protein oligomerization
[10]. However, its role remains unclear due to a lack of
structure-function information for this region, as X-ray
crystallography studies have been feasible only with the
C-terminally truncated form of cN-II (Δ537–561) [7, 9].
Fluctuations in cN-II activity have been observed in
various pathologies. The activity is upregulated in Lesch-
Nyhan syndrome [11], an inherited disorder of purine
metabolism that causes hyperuricemia and neurological
symptoms. High levels of cN-II expression have also
been correlated with poor prognosis in patients with
hematological neoplasias and solid tumors, regardless of
the therapeutic strategy [12]. In addition, cN-II activity
has been implicated in decreased therapeutic efficacy of
nucleoside analogs used for the treatment of cancer and
viral diseases [13].
Whole-exome sequencing studies have recently re-
vealed that somatic missense mutations in the gene en-
coding cN-II (NT5C2) are associated with relapsed acute
lymphoblastic leukemia (ALL) [14, 15]. The reported
mutations lead to biosynthesis of a hyperactive cN-II en-
zyme that boosts the viability of cancer cells in the pres-
ence of purine nucleoside analogs. These findings
demonstrate that cN-II is involved in chemoresistance of
leukemia cells and suggest that inhibition of hyperactive
mutants might become an efficient strategy for increas-
ing the success rates of the current chemotherapy
approaches [16]. However, the molecular mechanism
underlying the hyperactivity of the cN-II variants re-
mains unknown.
In this study, we describe the biochemical and structural
behavior of the three most common mutants: R367Q,
R238W, and L375F. Together, these mutants represent ap-
proximately 75 % of cN-II variants observed in patients
with relapsed ALL [14, 15, 17, 18]. Our work provides
structural insight into the impaired allosteric regulation of
ALL-specific cN-II mutants and forms a solid basis for de-
velopment of novel antileukemic therapies.
Results
ALL-specific mutations affect regulation of cN-II
To investigate the enzymological aspects of cN-II hyper-
activity, we examined kinetic properties of the most
frequently occurring mutants. Kinetic parameters were
determined in the presence or absence of the allosteric
activator ATP. The concentration of ATP (3 mM) used
in the enzyme assay reflected the physiological level of
this ligand [1]. The analysis of wild-type cN-II under
variable concentrations of ATP revealed that the enzyme
is fully active under such conditions (Additional file 1).
Examination of the full-length wild-type cN-II revealed
very low activity without ATP, as was demonstrated by
the large value (≈30 mM) of the Michaelis constant
(KM). Upon addition of ATP, the enzyme is stimulated,
and the KM value is decreased by 12-fold while Vmax is
not altered. The previous kinetic studies reported that
the ATP binding affected either both KM and Vmax [1] or
just Vmax [19]. The divergent results may be accounted
to different procedures during the protein preparation as
well as to a diverse biological source of the enzyme. We
used human recombinant protein expressed in bacteria,
while the other studies used material isolated from hu-
man placenta or calf thymus. Nevertheless, our kinetic
data are consistent with a role of cN-II activity in main-
taining homeostasis of purine nucleotides [20].
Analysis of the three full-length mutant enzymes re-
vealed that the variants exhibited different Michaelis
constants but similar turnover numbers (Table 1). When
compared to the wild type, all studied mutants had
lower KM in the absence of ATP, indicating that the
hyperactive variants are catalytically efficient even in the
absence of physiological activators. Moreover, the mu-
tants exhibited an abnormal response to the presence of
3 mM ATP in the reaction mixture. The addition of
ATP led to a large decrease in KM (12-fold) for the wild-
type enzyme, compared to only a moderate decrease
(2-fold) for the R367Q. In contrast, the R238W and L375F
mutants were stimulated by ATP to a higher extent than
the wild-type enzyme (23-fold and 76-fold decreases in
KM, respectively). Our data suggest that the R238W and
L375F mutations stimulate the catalytic activity in synergy
with the action of the allosteric activator, whereas the
R367Q variant adopts a fully active conformation even in
the absence of ATP.
In summary, our comprehensive enzyme kinetics study
reveals that all hyperactive variants have increased cata-
lytic activity, even in the absence of an allosteric effector.
Our results also suggest that the mutations do not have
a direct catalytic effect but rather impair the allosteric
regulation of the enzyme activity.
Mutants form tetramers with altered thermostability
As a next step, we studied the effects of the activating
mutations on the cN-II conformational properties. Be-
cause these mutations are distributed close to the inter-
subunit contact areas in the three-dimensional (3D)
structure of wild-type cN-II (Fig. 1a), we investigated
whether they affect conformational stability or tetramer
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formation. Using differential scanning fluorimetry (DSF),
we observed increased thermostability of the R367Q
mutant compared to the wild type, while the R238W
and L375F mutants exhibited decreased melting
temperature (Tm) values (Fig. 1b). To further examine
the thermostability of cN-II variants, we analyzed their
catalytic activity under varying temperature (Additional
file 2). The wild-type protein and the R367Q mutant dis-
played similar behavior, exhibiting the highest activity at
50 °C. Nevertheless, the R367Q mutant had a moder-
ately increased relative residual activity in the 45–55 °C
range. In contrast, the R238W and L375F mutants ex-
hibited maximal activity at only 45 °C, showing lower
catalytic efficiency at higher temperatures. These data
are consistent with the DSF observations and confirm
the effect of the mutations on the conformational stabil-
ity of the cN-II variants. Our results demonstrate that
the mutations cause an increase (R367Q) or decrease
(R238W and L375F) in the structural stability of the
cN-II protein.
Next, we used DSF to monitor the thermostability of
cN-II proteins under varying concentrations of ATP.
Our results showed that Tm values of both the wild-type
enzyme and the mutants increased in the presence of
ATP by more than 5 °C (Additional file 3). Such a high
degree of protein stabilization in an ATP concentration-
dependent manner strongly suggests that the effects are
caused by the binding event. To determine the binding
affinity of the cN-II variants towards ATP, we tested the
feasibility of isothermal calorimetry and microscale ther-
mophoresis. However, we could not obtain dissociation
constants due to a rather weak binding of the activating
compounds to the cN-II proteins with apparent Kd in
the low millimolar range [1]. As a surrogate, we used
saturation transfer difference nuclear magnetic reson-
ance (STD NMR) spectroscopy, which is a useful tech-
nique for probing of the low-affinity ligand binding [21].
We acquired the STD spectra of the variants in the pres-
ence of variable concentrations of ATP and specifically
followed the enhancement in the intensity of the ATP
signal. We observed a significant increase in the STD
enhancement of the ATP signals for all three studied
mutants relative to that of the wild-type protein at all
tested ligand concentrations (Additional file 4). These
experiments clearly showed that the altered allosteric
regulation of the mutants is accompanied by a higher
binding affinity towards the activator.
To assess the quaternary structures of the cN-II variants
(full-length as well as truncated), we used size exclusion
chromatography (SEC) and blue native polyacrylamide
gel electrophoresis (BN-PAGE). We observed that the
wild type and all the mutants migrated as biomolecules
of 250–300 kDa (Fig. 1c–e), corresponding to tetra-
meric assemblies. This finding was further confirmed
by small-angle X-ray scattering (SAXS) measurements
of the cN-II protein samples at various concentrations.
This analysis was feasible only for truncated enzymes
due to insufficient solubility of the full-length variants.
The wild-type and mutant proteins consistently exhib-
ited radii of gyration of ~5.0 nm and molecular weights
of ~260 kDa as determined by Guinier approximation,
which was in good agreement with the calculation of
the P(r) function. In addition, similar Porod volume
values of ~500 Å3 were obtained for all analyzed cN-II
variants (Fig. 1e; representative data for the wild type
are shown in Additional file 5). In summary, the results
of our experiments indicate that the mutations moder-
ately alter the protein stability but do not affect the for-
mation of homotetramers.
Mutation-induced structural changes are found at the
oligomeric interface
To gain detailed structural insight into the misregulated
cN-II mutants, we determined their 3D structures using
X-ray crystallography. We analyzed C-terminally trun-
cated variants, as previously described for wild-type
cN-II [7, 9]. Our kinetic analysis, together with DSF and
SEC measurements, showed that the full-length and
C-terminally truncated enzymes are essentially identical
(Additional files 6, 7, and 8). Therefore, the truncated vari-
ants can be considered suitable models to provide relevant
structural data.
Table 1 Kinetic parameters of cN-II enzymes in the presence and absence of ATP
Enzyme ATP Vmax [μmol.min
-1mg-1] Km [mM] n kcat (s
-1) kcat/Km [mM.s
-1]
Wild-type – 26.4 ± 4.7 33.5 ± 9.1 1.27 ± 0.38 29.5 ± 2.1 0.88 ± 0.25
Wild-type + 31.6 ± 1.8 2.9 ± 0.8 0.90 ± 0.14 35.3 ± 2.1 12.3 ± 3.3
R367Q – 31.4 ± 2.9 5.8 ± 1.7 0.88 ± 0.16 35.1 ± 3.3 6.0 ± 1.8
R367Q + 28.8 ± 1.3 2.8 ± 0.8 0.85 ± 0.10 32.2 ± 1.5 11.4 ± 2.1
R238W – 23.4 ± 1.9 12.1 ± 3.1 0.85 ± 0.09 26.1 ± 2.1 2.1 ± 0.6
R238W + 31.2 ± 2.5 0.52 ± 0.25 0.54 ± 0.15 34.8 ± 2.8 67 ± 33
L375F – 36.2 ± 3.9 12.2 ± 3.9 0.78 ± 0.10 40.5 ± 3.4 3.3 ± 1.1
L375F + 29.5 ± 2.3 0.16 ± 0.08 0.49 ± 0.16 33.0 ± 2.6 206 ± 105
The n value refers to the calculated Hill coefficient
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Crystals of all three cN-II mutants belonged to the
I222 space group with one molecule per asymmetric
unit. We solved their structures by the difference Fourier
technique using the isostructural wild-type structure [7].
Overall, the spatial arrangements of the mutants were
almost identical to that of the wild type. The root-mean-
square deviation (RMSD) values for superposition of 465
Cα atoms of individual mutants with the wild type were
approximately 0.5 Å, indicating that the mutations do
not induce large conformational changes in the protein.
Fig. 1 Oligomerization and thermostability of ALL-specific cN-II mutants. a Distribution of the identified mutations within the 3D structure of cN-II (Protein
Data Bank [PDB] ID 2XCX; missing loops were modeled using the ModLoop server). The mutants studied in this work (R367Q, R238W and L375F) are
highlighted using a boldface font and thick lines. Each subunit is represented in a different color. b Thermostability of cN-II proteins studied by differential
scanning fluorimetry. Each sample was measured twice in two independent measurements. c Size exclusion chromatography of full-length cN-II protein.
Elution volumes together with estimated molecular weight are summarized in the table (e). d Blue native polyacrylamide gel electrophoresis (BN-PAGE) of
the studied full-length proteins. The protein samples (5 μg) were loaded as follows: M molecular weight standard, S β-amylase from sweet potato
(200 kDa), 1 wild type, 2 R367Q, 3 R238W, 4 L375F. e Table summarizing data for the cN-II variants obtained from size exclusion chromatography and
small-angle X-ray scattering (SAXS). Analysis of proteins with 1 mg/ml concentration is shown. The values of Rg and MWGuinier were calculated by Guinier
approximation; Dmax and Porod volume were determined using fitting of distance distribution functions
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Nevertheless, detailed analysis revealed significant per-
turbations within the amino acid substitution micro-
environment in each mutant (Fig. 2).
The R367Q mutation is located in beta-strand 14
(amino acid residues 367–371) in the proximity of helix
A, which is a crucial regulatory segment of cN-II. The
replacement of the positively charged arginine residue
by a glutamine led to loss of residue 367 hydrogen bond-
ing interactions with both the carbonyl group of S40 and
the carboxyl group of D459. Consequently, D459 formed
a compensatory polar contact with K361, a residue lo-
cated in helix A, as illustrated in Fig. 2a. This interaction
likely stabilizes the helix A region, which directly stimu-
lates the catalytic activity of mutant cN-II.
The R238W mutation lies in alpha-helical region 9
(amino acid residues 231–242), which forms intersubunit
contacts with a region spanning residues 385–433 of the
adjacent subunit. We found structural differences between
wild type and the R238W mutant mainly in residues 397–
405. This segment was unstructured in the R238W mu-
tant but adopted a helical arrangement in the wild-type
protein (Fig. 2b). The helical structure was stabilized by its
interactions with residues 474–480 of the adjacent sub-
unit, and these contacts were found only in the wild-type
structure. In addition, in the R238W mutant, the W238
side chain mutant was reoriented to avoid steric hindrance
with F473, inducing changes within the interhelical loop
at the N-terminal region (amino acid residues 3–30).
Overall, the R238W mutation causes local changes, mainly
at the oligomeric interface of cN-II.
The L375F mutation is located in alpha-helix 13
(amino acid residues 375–381), which interacts with a 3/
10 helix (amino acid residues 485–487) in the neighbor-
ing subunit. Introduction of F375 induced a closer con-
tact between the mutated residue and H486 of the
adjacent subunit, which was accompanied by a slight
displacement of the proximal L379 side chain (Fig. 2c).
Consequently, this led to rearrangement of other sur-
rounding interactions at the oligomeric interface; i.e., the
NE1 atom of W382 formed a hydrogen bond with the
carbonyl group of H486 in the mutant and with the
D487 carbonyl in the wild type. Our data show that the
L375F mutation causes local changes at intersubunit
contacts.
To study distant structural effects of the mutations, we
thoroughly analyzed superpositions of the hyperactive vari-
ants’ structures with the previously published structure of
the wild-type enzyme apo form (PDB ID 2XCX) [9]. This
revealed that major changes are consistently distributed
across the oligomeric interface in the cN-II mutants
(RMSD> 0.8 Å; Fig. 3). This observation indicates that local
effects of the mutations propagate through the entire struc-
ture of cN-II and alter both contact areas responsible for
oligomerization: interfaces A and B. The most significant
changes at interface A (RMSD ≈ 1.2 Å) occurred within the
regions between residues 385–433 and 470–486, which are
in mutual contact and form a peripheral part of the
oligomerization site (Fig. 3d). Major perturbations at inter-
face B included an exclusive formation of antiparallel beta-
sheets in the mutants, which very likely induced other
changes in this region (RMSD ≈ 1.0 Å; Fig. 3c).
Interestingly, interface A also includes helix A (amino
acid residues 355–365), which was well defined in all the
mutant crystal structures. Helix A is formed only in the
Fig. 2 Local conformational changes in the cN-II mutants revealed by
X-ray crystallography. Wild-type protein subunits are colored in light/dark
gray, mutant subunits are colored in yellow or orange, and relevant
residues are represented as sticks. Mutated residues are highlighted with
boldface font. a The R367Q mutation disrupts the local hydrogen
bonding network. b The R238W substitution triggers changes at the
oligomeric interface. The region spanning residues 385–410 adopts a
helical arrangement in the wild type, while it is unstructured in the
mutant. Missing loops were modeled using the ModLoop server
(highlighted in blue and magenta for wild type and mutant, respectively).
c The L375F mutation alters local intersubunit contacts due to steric
hindrance of the more bulky phenylalanine residue
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active state of the cN-II enzyme [9], and the stabilization
of this region in the mutants is consistent with their
high catalytic potency even in the absence of ATP. Fur-
thermore, the superpositions of the mutants with the
ATP-bound wild-type structure (PDB ID 2XCW) yielded
reduced RMSD values in comparison to the values ob-
tained for the wild-type structure in the absence of ATP
(Fig. 3f ), indicating the constitutively active state of mis-
regulated variants.
To gain further insight into the rearrangement at the
oligomeric interface of the mutants, we analyzed intersu-
bunit contacts using Protein Interfaces, Surfaces and As-
semblies (PISA) software [22]. The results confirmed
differences in the pattern of intersubunit interactions at
both interfaces that were accompanied by a moderate
decrease in oligomerization area of the hyperactive vari-
ants (Fig. 3 and Additional file 9). In the mutants, the
interface A regions were extensively rearranged and
formed by unique polar interactions that were not found
in the wild-type protein. These unique interactions rep-
resented nearly half of all polar intersubunit contacts in
the studied cN-II variants. On the other hand, the
mutants had a smaller number of hydrophobic inter-
actions, which was reflected by a twofold lower solv-
ation energy in interface A (Fig. 3b and Additional
file 9). In contrast, the changes in interface B were
located predominantly within one specific segment
that was altered due to the formation of the antipar-
allel beta-sheet in the mutants (Fig. 3c).
In summary, the analysis of crystal structures demon-
strates that all studied mutations induce topological
changes almost exclusively at the oligomerization sites of
the cN-II tetramer. These results show that the muta-
tions, regardless of their position within the protein,
cause essentially identical structural perturbations
(Fig. 3a and e). This defines a common molecular mech-
anism of hyperactivation for all studied variants. X-ray
crystallography revealed that the local changes induced
by each point mutation propagate throughout the entire
biomolecule, causing the rearrangement within the olig-
omeric interface of cN-II. These alterations are also ac-
companied by the stabilization of helix A, which had
been previously identified as a major structural compo-
nent in the cN-II allosteric network. Therefore, our data
provide detailed mechanistic insight into how ALL-
specific mutations cause hyperactivity.
Conformational changes are accompanied by altered
protein dynamics
To further examine the effects of the mutations, we
studied the full-length wild-type and mutant cN-II pro-
teins in solution. Using hydrogen/deuterium exchange
(HDX) mass spectrometry, we examined the microenvir-
onment of the backbone amide protons.
Consistent with the crystallographic data, HDX
showed that perturbations in the mutants are localized
mainly at the oligomeric interface of the cN-II protein
(Fig. 4). Moreover, all studied mutants exhibited altered
HDX kinetics in essentially identical regions, supporting
the assumption that the variants share a common struc-
tural mechanism underlying enzyme misregulation. We
identified regions with altered exchange rates at both
oligomeric interfaces. In particular, interface A exhibited
faster HDX in the mutants than in the wild-type protein,
suggesting a more open conformation. In contrast,
interface B had slower exchange rates in the mutants,
indicating a higher rigidity within this region when
compared to the wild type. These observations are in
agreement with the structural changes identified by X-
ray crystallography.
Furthermore, HDX measurements provided insight
into the behavior of cN-II proteins that was not captured
by crystallography (Fig. 4b). Peptides spanning helix A
exhibited fast HDX in the wild type as well as in the mu-
tants, indicating a high degree of conformational flexibil-
ity for this segment (a comparison with peptides from
fully structured regions of cN-II is shown in Fig. 4b). In
addition, the region containing active site residue D52
(See figure on previous page.)
Fig. 3 Global structural changes observed in cN-II hyperactive mutants. a Structural changes in the R367Q mutant revealed by its superposition with
the wild-type cN-II (PDB ID 2XCX). The subunits of cN-II tetramer are represented as a light gray surface or dark gray ribbons. The residues with altered
positions of Cα atoms are shaded according to the calculated RMSD values. The active site and mutated residues are highlighted as blue and green
spheres, respectively, in one of the protein subunits. b Altered intersubunit interactions in the R367Q mutant. Cartoon representations (colored in light
blue) illustrate altered intersubunit contacts in the mutant protein, i.e., loss of contact (highlighted as green spheres), formation of a compensatory
interaction between subunits (red spheres), and residues with altered binding partners (orange spheres). c Detail of interface B within the wild type and
the R367Q mutant. Each subunit is shown in a different color: light and dark gray (wild type) or yellow and orange (R367Q). Residues involved in altered
intersubunit contacts are shown as sticks. The beta-sheet structure observed only in the mutants is highlighted. d Segments with the highest RMSD
values located within interface A of the R367Q mutant. These regions are shown in cartoon representation, with subunits in different colors. The
interhelical loop spanning residues 405–416 was not found in the crystal structure and was modeled using the ModLoop server for illustration. e
Structural changes observed in the R238W (PDB ID 5L4Z) and L375F mutants as revealed by a superposition with the wild-type structure (surface
representation) and by analysis of polar intersubunit contacts (cartoon representation). Coloring is identical as for the R367Q mutant (panels a and b).
f Superposition of the structures obtained for the studied mutants with the ATP-bound wild-type cN-II structure (PDB ID 2XCW). The coloring is
identical as for the structures in panels a, b, and e
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(residues 47–54) exhibited increased exchange rates in
each mutant. This indicates that conformational changes
in hyperactive mutants are transmitted to the catalytic
pocket, resulting in increased solvent accessibility at the
active site. Importantly, this observation provides a dir-
ect link between the remote conformational changes and
the hyperactivity of mutant enzymes.
To further analyze differences observed by HDX, we
focused on the perturbed regions in crystal structures.
Using RINalyzer [23], we examined residue interaction
networks in the wild type and the studied mutants. This
analysis revealed that most differences observed with
HDX could be explained by conformational changes ac-
companied with altered intramolecular interactions (see
comparison of HDX data with analysis of crystal struc-
tures in Additional file 10). However, a relatively small
number of regions with perturbed HDX had unaltered
topology in the crystal structures. This suggests that
these segments had different structural flexibility that
could not be captured using X-ray crystallography. Over-
all, HDX recorded conformational changes predomin-
antly at the oligomeric interface of the cN-II mutants,
thus supporting observations from X-ray crystallography.
Moreover, HDX measurements provide complementary
data about the dynamic behavior of cN-II proteins.
To further probe the flexibility of helix A, we analyzed
this segment within the wild-type enzyme and the
R367Q mutant, a variant locked in a catalytically active
state. Because this region is positively charged and con-
tains three lysine residues (K359, K361, and K362), we
performed amine-reactive chemical crosslinking com-
bined with mass spectrometric analysis. Crosslinking
reactions of wild-type cN-II and the mutant with bis(sul-
fosuccinimidyl)glutarate (BS2G) and bis(sulfosuccinimi-
dyl)suberate (BS3) provided 13 and 9 unique crosslinked
and one-site modification-containing peptides, respect-
ively (Additional file 11). Quantitative comparison of
crosslinking in the wild-type and R367Q enzymes re-
vealed several products with altered abundance (Table 2).
Interestingly, the identical crosslinking pattern and simi-
lar changes between wild type and mutant were also
observed in the proteins complexed with ATP. Differen-
tially modified sites were found in the intersubunit con-
tact area and/or close to helix A. In particular, peptides
containing a K344-K359 crosslink or one-site modifica-
tion of K344 were more abundant in the wild-type cN-II.
Fig. 4 Structural changes in the cN-II mutants captured by H/D exchange. a Perturbations of all analyzed mutants are observed mainly at the oligomeric
interface. Regions with faster (red) or slower (blue) deuteration kinetics in the mutants (related to the wild-type protein) are highlighted on the cN-II
tetramer. The perturbed regions are indicated only at two subunits (surface representation) of tetramer. Graphs (percentage of deuteration) show detailed
kinetics of these regions (black circle wild type, blue triangle R367Q, red square R238W, green diamond L375F). b HDX provides additional insight into
functionally important sites in cN-II proteins. In particular, faster exchange of active site region in the mutants and high level of deuteration for helix A in
all cN-II variants are shown. In addition, HDX kinetics of structured regions that do not exhibit significant changes are shown for illustration
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This observation is consistent with the crystal structures
of cN-II proteins because K344 is localized in a region
with altered intersubunit contacts (Fig. 5a). Furthermore,
we detected K359-K361 crosslinks and one-site modifi-
cation of K359 to a greater extent in the R367Q mu-
tant. These changes likely reflect a lower reactivity of
K344 and a subsequently lower amount of K344-K359
in the mutant.
We identified a K359-K361 crosslink at the region
forming helix A. However, we would expect the structur-
ally constrained positions of lysine residues within this
helical segment to prevent crosslinking (Fig. 5a). The
Table 2 Differentially modified lysine residues revealed from mass spectrometric study of protein crosslinking in the presence and
absence of ATP
Relative abundance (wild type compared to R367Q)
Protein:BS2G molar ratio Protein:BS3 molar ratio
Peptide Modified residues ATP 1:20 1:50 1:20 1:50
343–361 Lys 344; Lys 359 – 77-23 ± 20 88-12 ± 12 47-53 ± 24 65-35 ± 1
+ 88-12 ± 12 89-11 ± 11 62-38 ± 33 52-48 ± 43
345–362 Lys 359; Lys 361 – 37-63 ± 4 48-52 ± 13 20-80 ± 11 19-81 ± 5
+ 55-45 ± 5 43-57 ± 23 53-47 ± 5 44-56 ± 3
345–361 Lys 359 – 24-76 ± 11 34-66 ± 15 17-83 ± 12 14-86 ± 14
+ 24-76 ± 8 32-68 ± 18 30-70 ± 8 17-83 ± 8
343–359 Lys 344 – 80-20 ± 16 82-18 ± 10 94-6 ± 4 76-24 ± 13
+ 84-16 ± 16 85-15 ± 4 100-0 93-7 ± 7
Relative abundance refers to quantitative comparison between products obtained from wild-type cN-II and the R367Q mutant. Each value represents the mean
and standard deviation from three experiments
Fig. 5 High degree of flexibility for helix A in hyperactive cN-II mutants. a Crosslinked lysine residues located around helix A as identified by mass
spectrometry. Crosslinks K344-K359 and K359-K361 were detected even in R367Q, despite the constrained position of residues within the helical
region. Solid or dashed arrows indicate lysine crosslinks with higher or lower quantity, respectively, in the particular variant. The R367Q-specific
polar intersubunit contact between N117 and K344 is highlighted as a red dashed line. The loop spanning residues 355–365 was modeled in the
wild type using the ModLoop server due to missing electron density in this region. b Alternative conformations of the residues distributed within
or around the helix A of the cN-II mutants as observed by X-ray crystallography (highlighted as orange or magenta sticks)
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K359-K361 product was present in the wild-type and
R367Q enzymes, indicating that the helix A moves dy-
namically in both proteins. X-ray crystallography showed
that this region is unstructured in the wild type but
well-ordered in the mutant. Nevertheless, we identi-
fied several residues within helix A or in its vicinity
in alternative conformations in the crystals of all mu-
tant variants (Fig. 5b). Overall, these data show that
helix A fluctuates between the ordered and disordered
state, even in the active conformation of cN-II (i.e.,
wild type in the presence of ATP and the hyperactive
variants) with a properly ordered helical segment in
crystal structure. This indicates that the cN-II activity
is regulated by a conformational selection or by the
shifts in population of the pre-existing conformers,
which are well-recognized mechanisms for protein al-
lostery [24, 25].
In summary, mass spectrometry-based approaches
provided further insight into the behavior of the studied
proteins in solution. These results are consistent with
those of X-ray crystallography, identifying intersubunit
contact areas including helix A as key regions for regula-
tion of cN-II activity. Mass spectrometric analyses also
provided additional structural information, in particular
regarding mutation-induced changes within the active
site and the conformational flexibility of helix A.
Discussion
Whole-exome sequencing studies have shown that acti-
vating mutations in NT5C2 confer chemoresistance in
ALL [14, 15]. To elucidate the molecular mechanism
underlying the hyperactivity of cN-II mutants, we scruti-
nized the kinetic and structural behavior of three repre-
sentative variants (R367Q, R238W, and L375F). We
found that the ALL-specific variants are catalytically
efficient even in the absence of an allosteric activator,
demonstrating that the mutations cause misregulation of
cN-II activity.
Using X-ray crystallography combined with HDX and
protein crosslinking, we demonstrated that this misregu-
lation is caused by conformational changes at the oligo-
meric interface of the protein. Our data showed that cN-
II activation is associated with an altered pattern of
intersubunit interactions accompanied by differences in
dynamic behavior at the oligomeric interface. These
changes also include stabilization of helix A, a segment
that plays a crucial role in cN-II activation.
The role of intersubunit contacts in enzyme regulation
was further demonstrated by targeted analysis of the avail-
able structural data (Additional file 12). In particular, the
activator binding site and helix A are localized within
interface A, and the access channel to the active site is
formed by interface B. Moreover, superposition of the
available crystal structures of wild-type cN-II (PDB IDs
2XCX and 2XCW) reveals specific changes in residues
located at the oligomeric interface depending on the
presence or absence of allosteric activators. In addition,
the distribution of misregulation-causing mutations
within the cN-II structure strongly suggests that the
oligomerization sites play an essential role in allosteric
regulation (Fig. 1a). A structure of wild-type cN-II in com-
plex with noncompetitive inhibitors [26], which induce
major perturbations at the regions forming intersubunit
contacts, also demonstrates the importance of the oligo-
meric interface for cN-II regulation. Overall, we brought
together several lines of evidence indicating that the oligo-
meric interface is involved in regulation of cN-II.
Helix A is a crucial region for cN-II allosteric regula-
tion. Importantly, our study provided novel insight into
its behavior. Structural comparison of wild-type cN-II
and the hyperactive mutants revealed that helix A is well
ordered only in an active conformation of cN-II. How-
ever, mass spectrometry-based techniques showed that
helix A retains a certain degree of flexibility even in the
active state of the enzyme. This observation was further
supported by crystal structures of hyperactive mutants
that revealed alternative conformations of several resi-
dues within or around helix A (Fig. 5). However, the
techniques applied could not fully capture differences in
the rapid order-disorder transition between the wild type
and mutants. One may speculate that an active form of
cN-II contains a transiently ordered helix A that is fur-
ther stabilized in the crystallized proteins.
Here, we thoroughly characterized the most common
ALL-specific cN-II mutants. The studied variants are
representative of the structural topology of the majority
of all described mutations [14, 15, 17, 18]. The muta-
tions are localized in two regions: either close to helix A
(represented by R367Q) or directly at the intersubunit
contact area (represented by R238W and L375F; see
Additional file 12). The positioning of the mutated resi-
dues within the protein structure corresponded to their
kinetic properties and altered thermostability. In particu-
lar, the R367Q variant adopted a fully active conform-
ation that exhibited higher thermostability than the
wild-type enzyme. On the other hand, the R238W and
L375F mutations stimulated catalytic activity in synergy
with ATP binding and caused a decrease in protein ther-
mostability. Based on these observations, the activating
mutations can be divided into two major groups. One
group comprises mutations that directly stabilize the
neighborhood of helix A (R39Q, K359Q, S360P, and
R367Q). This mode of action was previously suggested
for K359Q, while other mutants lacked structural cues
explaining hyperactivity [14]. The second group includes
oligomeric interface mutations that alter intersubunit
contacts (R39Q, R238W, R238G, R238L, R291W,
K359Q, L375F, D407A, D407Y, S408R, P414S, and
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S445F). The R39Q and K359Q mutations belong to both
groups, as they may stabilize helix A while affecting
intersubunit contacts. These findings imply that the cN-
II structure contains two hotspot regions where point
mutations can cause enzyme hyperactivity.
Note that the relapsed ALL-specific NT5C2 mutations
are heterozygous and complement the wild-type allele.
Consequently, cN-II tetramers can be formed by two dif-
ferent subunits. It is tempting to speculate that muta-
tions induce hyperactivity even in the wild-type subunit
via allosteric transmission through the oligomeric inter-
face. Exploration of this phenomenon is beyond the
scope of the present study, but should be investigated in
the future.
Our enzyme kinetics analysis showed that cN-II mu-
tants are not properly regulated and are catalytically ef-
fective even in the absence of activators. It is tempting
to speculate that hyperactive mutants circumvent
physiological feedback inhibition of the enzyme in
order to persistently inactivate nucleoside analogs in
chemoresistant leukemic cells. As a consequence, the
elevated cN-II activity affects nucleotide metabolism
homeostasis. We propose that misregulation of purine
nucleotidase may represent a common mechanism
underlying chemoresistant leukemia driven by muta-
tions in NT5C2 (Fig. 6).
Interestingly, misregulation of mutated PRPS1, an
enzyme responsible for the first step of de novo pur-
ine synthesis, was recently confirmed as another
cause for chemoresistance in relapsed ALL [27]. This
strongly supports the notion that misregulation of
purine metabolism affects the outcome of chemother-
apy drugs targeting nucleotide metabolism. However,
the list of proteins that play a role in drug metabol-
ism remains incomplete. For example, MutT homolog
2 (MTH2) was recently implicated in the metabolism
of purine nucleoside analogs [28, 29]. Indeed, the
R139C variant of MTH2 causes intolerance to mer-
captopurine during the treatment of ALL or Crohn’s
disease [30, 31]. These findings jointly demonstrate
that drug metabolism and its regulation, including the
effects of genetic variations, need to be further inves-
tigated to improve the efficacy of currently used
therapeutic strategies.
In summary, our data provide comprehensive insight
into the allosteric regulation of cN-II, which could be used
for the design of novel antileukemic drugs. Our study im-
plies that the oligomeric interface in the cN-II protein rep-
resents a potential target for pharmacological intervention.
Importantly, the intersubunit contact area contains effector
sites that bind physiological ligands [7, 9, 32]. Recently,
low-affinity noncompetitive inhibitors have been developed
Fig. 6 Mechanism underlying chemoresistant ALL driven by mutations in NT5C2. Mutations located either in the vicinity of helix A or at the
oligomerization sites induce misregulation of cN-II activity through conformational modulation of the oligomeric interface, which boosts the
viability of tumor cells during chemotherapy
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to target this site in wild-type cN-II [26]. In addition,
oligomerization sites have been successfully targeted
in various screening campaigns against medicinally
relevant proteins (e.g., p53, tumor necrosis factor, and
G-protein coupled receptors) [33]. Moreover, allosteric
sites of metabolic enzymes, such as pyruvate kinase,
isocitrate dehydrogenase (IDH), and glutaminase, have
been proposed as important targets for specific cancer
therapies [34]. Potent allosteric inhibitors of glutamin-
ase [35] and tumor-specific IDH2 [36] mutants are
currently being tested in clinical trials [37].
Conclusion
Our study clearly demonstrates that ALL-specific muta-
tions cause misregulation of cN-II due to allosteric modula-
tion of the oligomeric interface, as illustrated in Fig. 6. This
defines a common molecular mechanism underlying che-
moresistance driven by hyperactive purine nucleotidase.
Allosteric inhibition of cN-II mutants may become an ef-
fective therapeutic approach for treatment of ALL.
Methods
Materials
Except where stated otherwise, all compounds were pur-
chased from Sigma-Aldrich.
Cloning and plasmid preparation
All plasmids were derived from pET28 expressing C-
terminally truncated human cN-II (Δ 536–561) with an
N-terminal hexahistidine tag (Source Bioscience, UK) as
previously described [7]. Site-directed mutagenesis was
performed using the QuikChange Site-Directed Muta-
genesis Protocol (Agilent Technologies). To prepare
plasmids producing full-length proteins, the region en-
coding the C-terminal tail was prepared synthetically
(Eurofins Scientific) and ligated into the constructs en-
coding the truncated variants.
Protein expression and purification
Protein samples were prepared according to previously
described procedures [7] with several modifications.
Fractions collected from nickel affinity chromatography
that contained cN-II protein were further purified using
ion-exchange columns. Full-length proteins were dialyzed
against 50 mM Bis-Tris propane (pH 7.0) containing
10 % glycerol and 2 mM tris(2-carboxyethyl)phosphine
(TCEP; buffer A) and subsequently loaded onto a
MonoQ column (Amersham Biosciences) and eluted
with a gradient of NaCl (0–1 M) in buffer A over 30
column volumes. The C-terminally truncated variants
were dialyzed against 50 mM sodium phosphate (pH 6.7)
containing 10 % glycerol and 2 mM TCEP (buffer B),
loaded onto a MonoS column (Amersham Biosciences),
and eluted with a gradient of NaCl (0–1 M) in buffer B
over 30 column volumes. Fractions containing cN-II were
collected and dialyzed against 50 mM sodium phosphate
(pH 7.4) containing 100 mM NaCl, 10 % glycerol, and
2 mM TCEP and stored at –80 °C.
Proteins were purified to homogeneity as judged by
silver-stained SDS-PAGE. The identity of the purified
cN-II proteins was validated by mass spectrometry-
based peptide mass fingerprinting.
Assay of cN-II activity
The catalytic activity of cN-II was assessed with inosine
monophosphate (IMP) as a substrate according to a previ-
ously described procedure [1]. The nucleotidase activity
(0.1 μM cN-II subunit) was measured in the presence or
absence of 3 mM MgATP, with the IMP concentrations
ranging between 10 μM to 60 mM, in 60 mM imidazole
buffer (pH 7.4) containing 150 mM KCl, 1 mM MgCl2,
and 0.5 mM dithiothreitol (DTT). The reaction was per-
formed at 37 °C for 1–20 minutes and then chilled on ice
and quenched with 0.15 M ethylenediaminetetraacetic
acid. The rate of enzymatic conversion was analyzed using
reversed-phase high-performance liquid chromatography.
Components in the reaction mixture were separated on a
Gemini 5 μm C18 110 Å column (Phenomenex) by iso-
cratic elution with 0.1 M triethylammonium bicarbonate,
and signals were obtained using UV detection at λ =
262 nm. The enzyme activity was evaluated by integrating
of the peaks with mobility corresponding to the standards
of substrate and product. Nonlinear data fitting was per-
formed using OriginPro 8.5 (OriginLab). The linearity of
the assay was tested in the presence and absence of ATP
during a reaction time of 20 minutes as illustrated in
Additional file 1. Kinetic properties of the wild-type cN-II,
including a response upon ATP binding, were in
agreement with a previous study on human recombin-
ant enzymes [10] and with reports deposited in the
BRaunschweig ENzyme DAtabase (BRENDA).
Differential scanning fluorimetry
Proteins (0.1 mg/ml) were dissolved in 50 mM sodium
phosphate (pH 7.4) containing 100 mM NaCl, 2 mM
TCEP and 8× SYPRO Orange. To analyze the effect of
ATP on protein thermostability, the proteins were incu-
bated with the ligand for 10 minutes at room
temperature prior to addition of the SYPRO Orange dye.
Using a LightCycler 480 (Roche) real-time detection sys-
tem, the proteins were heated from 20 °C to 90 °C in in-
crements of 0.5 °C and with 1-minute hold intervals.
The signal was monitored by fluorescence detection (ex-
citation wavelength of 470 nm and emission wavelength
of 570 nm). The melting temperatures (Tm) of proteins
were determined as minima from first derivative curves.
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Saturation transfer difference NMR
All data for cN-II proteins were collected at 25 °C using
a Bruker Avance III™ HD 850 MHz spectrometer
equipped with a 5 mm CPTCI 1H/13C/15N/D Z-GRD
cryoprobe. In order to compare the relative ATP affin-
ities towards the cN-II variants, 1H STD NMR spectra
were acquired using 350-μl samples of 1.5 μM cN-II
proteins dissolved in 50 mM sodium phosphate buffer
(pH 7.4) containing 100 mM NaCl, 2 mM TCEP, and
5 % D2O/95 % H2O. The frequency used for non-
selective irradiation of the protein signals was 666 Hz
(0.78 ppm), using a 50-ms shaped pulse Eburp2.1000 at
a power of 40 dB. The spectra were acquired with a free
induction decay (FID) resolution of 0.83 Hz, and the
typical experimental time was 20 minutes.
Size exclusion chromatography
Proteins were dissolved in 50 mM sodium phosphate
(pH 7.4) containing 100 mM NaCl and 2 mM TCEP and
analyzed using a Superdex 200 10/300 GL column. The
column was calibrated with a high molecular weight
protein standards kit (Amersham Biosciences). For ana-
lysis, 200 μl of cN-II protein samples (0.5 mg/ml) were
injected.
Small-angle X-ray scattering
Truncated proteins of varying concentrations (from 0.25
to 2 mg/ml) dissolved in 50 mM sodium phosphate
(pH 7.4) containing 100 mM NaCl, 2 mM TCEP, and
5 % glycerol were analyzed at the BM29 beamline at the
European Synchrotron Radiation Facility (ESRF) (Gre-
noble) with a Pilatus 1 M detector. The measurements
were performed at a sample-detector distance of
2.864 m and a wavelength of 0.992 Å. Data were proc-
essed with PRIMUS [38], and the scattering curves were
analyzed using Guinier approximation to calculate the
forward scattering I(0) and radius of gyration (Rg). A so-
lution of β-amylase from sweet potato (200 kDa) was
used as a reference sample. Distance distribution func-
tions P(r), maximum particle dimensions Dmax [39], and
Porod volume were computed with GNOM [40]. All
used programs are included in the ATSAS software
package [41].
Blue native polyacrylamide gel electrophoresis (BN-PAGE)
BN-PAGE was performed using 4–16 % polyacrylamide
Bis-Tris precast gels (Invitrogen) at room temperature
according to the manufacturer’s protocol with high mo-
lecular weight native marker kit (Amersham Biosciences)
and β-amylase from sweet potato as protein standards.
A 5-μg aliquot of protein was loaded in each lane as de-
scribed previously [42].
X-ray crystallography
The C-terminally truncated mutant proteins lacking resi-
dues 537–561 were crystallized as described for wild-type
cN-II [7]. The proteins (8 mg/ml) in 100 mM sodium cit-
rate (pH 6.0) containing 2 mM TCEP were crystallized
using the hanging drop vapor diffusion technique. The
precipitant for each mutant was as follows: R367Q,
100 mM MES/imidazole (pH 6.5) containing 200 mM
NaCl, 30 % glycerol, and 10 % PEG 4 k; R238W, 100 mM
MOPS/HEPES-Na (pH 7.5) containing 100 mM NaCl,
15 % glycerol, and 10 % PEG 4 k; L375F, 200 mM MES/
imidazol (pH 6.5) containing 100 mM NaCl, 30 % glycerol,
and 10 % PEG 4 k. The crystals grew in 1.5-μl drops of 2:1
protein:precipitant solution for 1 week at room
temperature and subsequently were transferred into a
drop of perfluoropolyether for 20 s and then flash-frozen
in liquid nitrogen. Diffraction data were collected on
BL14.1 operated by the Joint Berlin MX Laboratory at the
BESSY II electron storage ring (Berlin-Adlershof,
Germany) [43]. Data processing was performed using the
XDS software package [44]. The 3D structure of the mu-
tants was solved by molecular replacement with the struc-
ture of wild-type enzyme (PDB ID 2J2C) as a template
using the MOLREP program [45]. Refinement was per-
formed with REFMAC 11.0 [46], including translation/
libration/screwing (TLS) refinement [47] with 12 TLS
groups at a later stage of refinement. Manual rebuilding of
the model was done using Coot [48]. The MolProbity ser-
ver [49] was used for assessment of the final model qual-
ity. Structural statistics are shown in Additional file 13.
The protein structures were analyzed using software in-
cluded in the CCP4 package [50], namely PISA [22],
LSQKAB [51], and BAVERAGE. In addition, the residue
interaction network was assessed with RINalyzer [23].
Structural models were visualized using PyMOL software
(DeLano Scientific). Missing loops were modeled using
the ModLoop server [52] to illustrate the possible position
of these regions in the protein structure. These are not
part of the models deposited in the PDB under accession
codes: 5K7Y (R367Q), 5L4Z (R238W), and 5L50 (L375F).
Hydrogen/deuterium exchange mass spectrometry
Full-length proteins (1 mg/ml) were dissolved in 20 mM
sodium carbonate (pH 7.4) containing 100 mM potas-
sium chloride, 1 mM magnesium chloride, and 0.5 mM
TCEP. Proteins were diluted to a final concentration of
0.2 mg/ml with the same buffer prepared in D2O (pD
7.4) to initiate HDX that was subsequently quenched at
varying time points by adding the same volume of 0.25 M
glycine-HCl buffer (pH 2.3) and immediately freezing the
samples on liquid nitrogen. Liquid chromatography-mass
spectrometry (LC-MS) analysis, including on-line pepsin
digestion, data acquisition, processing, and evaluation,
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was performed according to a previously described
procedure [53].
Chemical crosslinking studied by mass spectrometry
Full-length proteins (0.2 mg/ml) dissolved in 50 mM
triethylammonium bicarbonate (pH 7.4) containing
50 mM NaCl, 1 mM MgCl2, and 0.5 mM DTT were in-
cubated with the crosslinking agents BS2G and BS3 in
protein:crosslinker ratios of 1:20 and 1:50, respectively.
Reactions were carried out at room temperature for 1 h
and then quenched with 0.15 mM ethanolamine. Cross-
linked proteins were reduced with DTT, alkylated with
iodoacetamide, and digested using trypsin. To compare
the crosslinking pattern of wild type and R367Q, isotop-
ically labeled crosslinkers were used, and a quantitative
comparison of light/heavy crosslinked peptides was per-
formed by LC-MS as described elsewhere [54].
Crosslinked proteins were analyzed using SDS-PAGE
to check that the reactions did not yield nonspecific ag-
gregates (Additional file 14).
Additional files
Additional file 1: Validation of the enzyme assay. a The cN-II activity
under varying concentrations of ATP. The analysis was performed using
1 mM IMP as substrate. The points represent mean values with standard
deviation from four measurements. b The test of linearity for catalyzed
reaction for cN-II in the presence and absence of ATP. The analysis was
performed with 5 mM IMP as substrate. (TIF 421 kb)
Additional file 2: Temperature dependence of cN-II catalytic activity. The
activity values are relative to the values obtained at 40 °C with 1 mM IMP as
substrate. The points represent mean values from two independent
measurements. (TIF 452 kb)
Additional file 3: Thermostability of cN-II proteins in the presence of ATP
studied by differential scanning fluorimetry. a Representative curves of the
wild-type and mutant proteins in the presence or absence of 3 mM ATP.
b The Tm values of the cN-II proteins under varying concentrations of ATP.
Each point represents the mean value from two measurements. (TIF 1192 kb)
Additional file 4: 1H STD NMR spectra of ATP at various concentrations
in the presence of cN-II variants. The ATP reference 1H NMR spectrum
(standard atom numbering) is shown at the bottom. (TIF 1286 kb)
Additional file 5: Representative data from SAXS measurements:
analysis of wild-type cN-II (1 mg/ml). a Processed scattering curve. b
Guinier analysis. c Distance distribution analysis including calculation of
the P(r) function. (TIF 836 kb)
Additional file 6: Kinetic parameters of the C-terminally truncated
enzymes in the presence and absence of ATP. The n value refers to the
calculated Hill coefficient. (DOCX 15 kb)
Additional file 7: Differential scanning fluorimetry of the C-terminally
truncated cN-II variants in the presence or absence of 3 mM ATP.
Truncated proteins are stabilized upon ATP binding, as described for full-
length variants. Mean values and standard deviations from duplicates of
two independent measurements are listed. (DOCX 14 kb)
Additional file 8: Size exclusion chromatography of the C-terminally
truncated cN-II proteins that were studied by X-ray crystallography. Each
variant formed tetramers as reported for full-length proteins. The column
was calibrated using a high molecular weight protein standard kit
(Amersham Biosciences). (TIF 284 kb)
Additional file 9: Oligomeric interface of cN-II crystals analyzed by PISA.
NHB and NSB represent the number of identified hydrogen bonds and salt
bridges, respectively. Δi G is the energy of solvation. (DOCX 15 kb)
Additional file 10: Regions with perturbed deuteration kinetics
analyzed in crystal structures using RINalyzer. The ‘+’ and ‘-’ symbols refer
to the presence or absence of structural changes, respectively. (DOCX
15 kb)
Additional file 11: Cross-linking of the wild-type enzyme and R367Q
mutant: modified residues identified and quantified using mass spectrometry.
Relative abundance refers to a quantitative comparison between products
obtained from wild-type and R367Q. The type of crosslinking (i.e.,
intermolecular, intramolecular or hanging) was inferred from the mass
spectrometric data or from the crystal structure. Each number represents the
mean value and standard deviation from three experiments. (DOCX 18 kb)
Additional file 12: Structural analysis demonstrates an important role
for the oligomeric interface in cN-II allosteric regulation. a Position of
helix A (red dots) and the ATP binding site (orange dots) within the cN-II
tetramer. b The access channel towards the active site is formed by inter-
face B. Each subunit is highlighted in a different color; the active site resi-
due D52 is shown in red. c Superposition of wild type in its free state and
in complex with ATP (PDB IDs 2XCX and 2XCW). Differences in positions
of Cα atoms are highlighted in the structure of the apo form (PDB ID
2XCX). The active site residue (D52) is shown as blue spheres. d Location
of ALL-specific mutations reveals two hotspot regions. Each subunit is
depicted in a different color, and helix A is shown as an orange cylinder.
Mutated residues are highlighted as red spheres within one subunit
shown in ribbon representation (wheat colored). (TIF 10513 kb)
Additional file 13: Crystal parameters, data collection and refinement
statistics. (DOCX 20 kb)
Additional file 14: Representative SDS-PAGE of the wild-type cN-II
protein upon crosslinking reaction with bis(sulfosuccinimidyl)glutarate
(BS2G) and bis(sulfo-succinimidyl)suberate (BS3). M and N refer to
molecular weight marker and non-modified sample, respectively. The
protein:crosslinker molar ratio is indicated at the top of each lane. The
arrows indicate the number of subunits contributing to crosslinking
products. (TIF 1253 kb)
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